Elicio Therapeutics
PublicElicio Therapeutics is now publicly traded
The data on this page reflects Elicio Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Jan 5, 2024
Total Funding Raised
$7.05M
Company Overview
Elicio Therapeutics (NAS: ELTX) is a biotechnology company specializing in the development of innovative cancer immunotherapies aimed at patients with limited treatment options and poor outcomes.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Elicio Therapeutics Comparables
Compare Elicio Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nouscom | 76% | |
| Immunomic Therapeutics | 76% | |
| Treme Bio | 73% |
Elicio Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jan 5, 2024 |
Elicio Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access